New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer – What do we understand so far?
| Autor: | Kara Lombardo, Andres Matoso, Burles A. Johnson, Noah M. Hahn, Wm. Kevin Kelly, David J. McConkey, Babar Bashir, Jean H. Hoffman-Censits |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Response rate (survey) medicine.medical_specialty Bladder cancer medicine.diagnostic_test business.industry Urology 030232 urology & nephrology Enfortumab vedotin Subgroup analysis medicine.disease 03 medical and health sciences 0302 clinical medicine Tumor progression 030220 oncology & carcinogenesis Internal medicine Biopsy medicine Urothelial cancer In patient business |
| Zdroj: | Urologic Oncology: Seminars and Original Investigations. 39:619-622 |
| ISSN: | 1078-1439 |
| Popis: | Enfortumab vedotin (EV) was FDA approved in December 2019 for platinum- and checkpoint-refractory urothelial cancer based on an exceptional 44% response rate, and is currently approved for use after platinum and checkpoint inhibitor therapy. Enfortumab is an antibody-drug conjugate that targets Nectin-4, which is widely expressed in urothelial cancer. Despite this ample target, clinical benefit is not achieved by all patients, and mechanisms of treatment resistance are undescribed. Herein we summarize what is known to date regarding coorelative findings and subgroup analysis and EV response, including novel biopsy data in patients with tumor progression post EV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect